Connect with us

Biotech

Ship2B Ventures to Invest €1.5 Million in Early-Stage Ventures

On an international scale, one of the recent projects in which Ship2B Ventures has invested is Fosanis, a German company specializing in digital health. The Teutonic company is the developer of Mika, a personalized digital therapy platform (DTx) with prescription for all oncological diseases. Mika is a DTx in oncology to accompany people affected by cancer throughout their disease and therapy.

Published

on

Ship2B Ventures is betting on projects in development. The Spanish venture capital manager will allocate €1.5 million from the BSocial Impact Fund, which is 50% focused on digital health and MedTech initiatives, to investments in early-stage, pre-seed projects, according to Maite Fibla, co-founder of Ship2B and Ship2B Ventures.

Ship2B Ventures’ idea is to invest in around ten to fifteen early-stage projects, with tickets ranging from €100,000 to €200,000, Fibla said. “The rounds carried out by these companies will not exceed €1 million,” added the executive.

For now, Ship2B Ventures has invested in companies in the health sector such as Doctomatic, a Catalan company that offers a digital platform for the remote management and control of chronic patients; Rosita, a Valencian start-up that provides care services for the elderly, or The Smart Lollipop, a Catalan company that has created a smart candy that can detect and diagnose diseases such as hypercholesterolemia or celiac disease among children through a saliva sample.

Read more about Ship2B Ventures and find the latest financial news in the world with the Born2Invest mobile app.

Ship2B Ventures has backed companies such as Doctomatic, Rosita, and Fosanis

On an international scale, one of the recent projects in which Ship2B Ventures has invested is Fosanis, a German company specializing in digital health. The Teutonic company is the developer of Mika, a personalized digital therapy platform (DTx) with prescription for all oncological diseases.

Mika is a DTx in oncology to accompany people affected by cancer throughout their disease and therapy. Mika combines artificial intelligence (AI)-based monitoring and coaching, including scientifically proven methods and therapy management techniques.

SEE ALSO  The budget deficit in South Africa is growing at an alarming pace

The next project that Ship2B Ventures will participate in and that Fibla is advancing is Dana, a Spanish platform that offers emotional support for women during motherhood. The app is designed to improve the well-being of mothers from a preventive perspective and anticipating the onset of possible maternal mental health disorders that may arise during the perinatal period.

At the end of 2021, Ship2B Ventures, together with the European Union, the European Investment Fund (EIF), and Banco Sabadell, made the final closing of the BSocial Impact Fund with €55 million.

In the closing of BSocial Impact Fund, Ship2B Ventures added XesGalicia, a management company of venture capital entities 100% owned by Igape, among others, as an investor.

__

(Featured image by stevepb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.

Continue Reading